Soligenix, a development-stage biopharmaceutical company, has collaborated with the Infectious Disease Research Institute (IDRI) to develop select biodefense vaccines using synthetic adjuvants.

The collaboration will leverage IDRI’s synthetic adjuvants in conjunction with Soligenix’s proprietary subunit proteins and thermostability platform, known as ThermoVax.

IDRI adjuvant technology vice president, Darrick Carter, said that IDRI’s adjuvant technology can help build effective vaccines.

"The combination of the technologies is expected to result in vaccines with characteristics for long-term stability and onset of protective immunity."

"These new candidate vaccines could be the critical solution in providing protection to people in the event there is a bioterror threat from the release of anthrax or ricin toxins," Carter added.

The combination of the technologies is expected to result in vaccines with characteristics for long-term stability and onset of protective immunity, desired features of vaccines that would be stockpiled for emergency use.

The collaboration initially aims at evaluating the combination of one of IDRI’s adjuvant compounds that has been shown to enhance the generation of high-titer neutralising antibodies to anthrax toxin with VeloThrax, Soligenix’s second generation Dominant Negative Inhibitor subunit protein anthrax vaccine candidate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The second developmental objective is to appraise the combination of an IDRI adjuvant with formulations of RiVax, Soligenix’s vaccine against ricin toxin under development.

The research will initially be conducted under Soligenix’s existing $9.4m National Institute of Allergy and Infectious Disease grant, which supports the development of advanced heat stable vaccines against anthrax and ricin toxins.

Soligenix president and CEO Christopher Schaber said: "We believe that with the addition of IDRI’s potent adjuvants to our hyperimmunogenic anthrax and ricin toxin vaccines, we will have the potential to develop highly competitive biodefense vaccines that can address the exact needs of the US government with regard to rapid onset immunity with just one or two doses."